Institution
Hunan Cancer Hospital
- 340running trials
- 97closed trials
- 7,197publications (OpenAlex)
Running trials
Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Not yet recruiting
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Not yet recruiting
Recruiting
Not yet recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Recruiting
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
Recruiting
Recruiting
Not yet recruiting
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
Recruiting
Not yet recruiting
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
Recruiting
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Not yet recruiting
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Active, not recruiting
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Recruiting
Recruiting
Recruiting
Showing 50 of 340.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer85 recruiting
- Metastatic breast cancer18 recruiting
- Colorectal cancer15 recruiting
- Head and neck cancer14 recruiting
- Liver and biliary tract cancer14 recruiting
- Prostate cancer14 recruiting
- Gastric and oesophageal cancer12 recruiting
- Pancreatic cancer11 recruiting
- Bladder cancer10 recruiting
- Triple-negative breast cancer9 recruiting
- Ovarian cancer8 recruiting
- Cervical cancer7 recruiting
- Chronic lymphocytic leukaemia7 recruiting
- Endometrial cancer7 recruiting
- Diffuse large B-cell lymphoma6 recruiting
- Melanoma5 recruiting
- Sarcoma5 recruiting
- Childhood cancers3 recruiting
- Mantle cell lymphoma3 recruiting
- Kidney cancer2 recruiting
- Mesothelioma2 recruiting
- Neuroendocrine tumours2 recruiting
- Thyroid cancer2 recruiting
- Brain metastases1 recruiting
- Familial hypercholesterolaemia1 recruiting
- Follicular lymphoma1 recruiting
Closed trials
Terminated
Completed
Withdrawn
Completed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Completed
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Terminated
Recruiting
Completed
Completed
Completed
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
Completed
Completed
Completed
Completed
Terminated
Completed
Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC
Terminated
Completed
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Recruiting
Completed
Completed
Completed
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma
Completed
Completed
Completed
Completed
Completed
Completed
Recruiting
Completed
Completed
Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC
Completed
Terminated
Terminated
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
Completed
Completed
Completed
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Completed
Completed
Completed
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Showing 50 of 97.
Registry name variants (65)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Hunan Cancer Hospital
Changsha, Hunan 410013
357 trials
Hunan Cancer Hospital
Hunan, Hunan 410000
11 trials
Hunan Cancer Hospital - Oncology Department
Changsha, Hunan 410013
5 trials
Hunan Cancer Hospital (Site 0104)
Changsha, Hunan 410013
2 trials
Hunan Cancer Hospital (Site 0132)
Changsha, Hunan 410013
2 trials
Hunan Cancer Hospital (Site 0815)
Changsha, Hunan 410013
2 trials
Contact: Study Coordinator
Hunan Cancer Hospital (Site 1174)
Changsha, Hunan 410013
2 trials
Hunan Cancer Hospital (Site 3311)
Changsha, Hunan 410000
2 trials
Hunan Cancer Hopital
Changsha, Hunan 410031
1 trial
Hunan Cancer hospital
Changsha Shi, 410013
1 trial
Hunan Cancer Hospital
Changshang, Hunan 410013
1 trial
Hunan Cancer Hospital - 3209
Changsha, Hunan
1 trial
Hunan Cancer Hospital(Department II of Gastroenterology and Urology/Hepatobiliary Surgery)
Changsha, Hunan 410205
1 trial
Hunan Cancer Hospital
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital - Phase 1
Changsha, Hunan
1 trial
Hunan Cancer Hospital, Radioactive Interventional Department
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital - Radiology
Changsha, Hunan
1 trial
Hunan Cancer Hospital (Site 0027)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 0094)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 0168)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0182)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 0307)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0405)
Changsha, Hunan 410013
1 trial
NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Contact: Study Coordinator
Hunan Cancer Hospital (Site 0421)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 0503)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0515)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 0704)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0709)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0745)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0817)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 0826)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1015)
Changsha, Hunan 233004
1 trial
Hunan Cancer Hospital (Site 1312)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1403)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1411)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 1615)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1623)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1630)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 1763)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 2020)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 2112)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 2214)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 2232)
Changsha, Hunan 410006
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 2439)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 2440)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 2523)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 2608)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 2710)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 2822)
Changsha, Hunan 410013
1 trial
Contact: Study Coordinator
Hunan Cancer Hospital (Site 2905)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 2907)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3014)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3133)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3134)
Changsha, Hunan 410013
1 trial
NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Contact: Study Coordinator
Hunan Cancer Hospital (Site 3141)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3225)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3238)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 3334)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 4050)
Changsha, Hunan 410006
1 trial
Hunan Cancer Hospital (Site 5002)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 5021)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital (Site 6020)
Changsha, Hunan 410013
1 trial
Hunan Cancer Hospital - Thoracic Medicine Dept II
Changsha, Hunan
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
- Lung cancer215 works · 152 trials
- Ovarian cancer39 works · 21 trials
- Gastric and oesophageal cancer31 works · 36 trials
- Brain metastases27 works · 2 trials
- Metastatic breast cancer20 works · 37 trials
- Thyroid cancer13 works · 6 trials
- Diffuse large B-cell lymphoma10 works · 14 trials
Institution data: ROR 025020z88 (CC0-1.0)Updated 15 Nov 2026